ClinicalTrials.gg
CompletedNCT03442972GLP-2 BiopsyUpdated May 25, 2022

Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids

A Phase 2/3 interventional study of Teduglutide and Placebo in Hyperlipidemias, sponsored by University Health Network, Toronto. Completed at 2 sites in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-05-25.

Sponsored by University Health Network, Toronto · Phase 2/3, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hyperlipidemias by University Health Network, Toronto — none open to participants now, none under way, none of them phase 3. Hyperlipidemias · University Health Network, Toronto.

Enrollment
3rd of 11
21 · median 15
Started
2019
with 1 other
Phase 2/3
6 of 11
none open now
Registered
6th of 11
by date

Among the 11 studies in Hyperlipidemias by University Health Network, Toronto, this one is the 3rd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 2/3, and was the 6th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 11 studies in Hyperlipidemias by University Health Network, Toronto is open now. The open studies under Hyperlipidemias, anywhere →

Where they have run

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Hyperlipidemias by University Health Network, Toronto as a file.
02

Study summary

Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This triglyceride can then be released into the blood when another meal is consumed or in response to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride from the gut is not known. The research team in this study is interested in finding out how teduglutide (a degradation resistant form of GLP-2) releases stored triglyceride from the gut by studying samples from patients undergoing endoscopy and small bowel biopsy.

Read the detailed description

The release of stored enteral lipids will be investigated in 30 patients undergoing upper gastrointestinal endoscopy and duodenal biopsy for clinical indications. Patients undergoing the procedure will be recruited. Participants will have a high fat liquid meal as breakfast. 5 hours later, participants will be randomly assigned to receive either a subcutaneous injection of placebo (n=15) or a subcutaneous injection of the Health Canada approved glucagon-like peptide-2 (GLP-2) analogue (teduglutide, Revestive®, Shire Canada)(n=15 different subjects). 1 hour later, a duodenal biopsy specimen will be obtained from 2-3 sample sites,snap frozen in dry ice and stored at -80°C for further analysis.

03

Conditions studied

  • Hyperlipidemias

Browse trials for

Keywords

  • Intestinal lipoprotein
  • Duodenal biopsy
  • Gut Peptide
  • Chylomicrons
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, aged 18 to 60 years requiring endoscopy and duodenal for clinical indications, with no to the procedure, as judged by Dr. Bookman of the Kensington Screening Clinic, Toronto, ON, Canada

Exclusion criteria

Exclusion Criteria:

  • Patients with active inflammatory bowel disease
  • Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption
  • Patients with active bowel
  • Patients with diabetes mellitus or known/ suspected motility disorders of the gut
  • Patients with decompensated liver disease
  • Patients on ezetimibe or bile acid sequestrants
  • Patients who are pregnant or breastfeeding.
  • Patients with renal disease
  • Patients on benzodiazepine
  • Unstable cardiac or respiratory disease
  • Any changes to medication in the preceding month
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Teduglutide

    Teduglutide, up to 0.05mg/kg, subcutaneous, single dose

    Drug: Teduglutide

  • Placebo comparator
    Placebo

    Placebo, subcutaneous, single dose

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Release of enteral lipids in response to teduglutide

    To quantify the difference in amount of enteral lipids between GLP-2 and placebo treatment

    Time frame: 6 hours

07

Study locations

2 sites
  • Toronto General Hopital
    Toronto, Ontario M5G 2C4, Canada
  • Kensington Screening Clinic
    Toronto, Ontario M5T 3A9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jun 2021, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2018
First posted
Feb 22, 2018
StartActual
Jan 17, 2019
Primary completionActual
Jun 1, 2021
CompletionActual
Dec 1, 2021
Last update
May 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03442972
Collaborators
Kensington Screening Clinic
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Jan 17, 2019
Primary completion
Jun 1, 2021
Completion
Dec 1, 2021
Last update
May 25, 2022

Study contacts

Gary F Lewis, MD
principal investigator · UHN

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion